A Study of Histamine H2 Antagonists Effect on Survival Rate in Colorectal and Gastric Cancer Patients: A Meta-Analysis
Novelty in Biomedicine,
Vol. 13 No. 4 (2025),
28 October 2025
,
Page 254-260
https://doi.org/10.22037/nbm.v13i4.48876
Abstract
Background: Histamine H2 antagonists (H2RAs) are hypothesized to inhibit suppressor T-lymphocyte function, with preliminary evidence from randomized trials suggesting potential prolongation of survival in patients with operable and inoperable gastric and colorectal cancers. In this meta-analysis, we aimed to investigate the impact of these antagonists on the survival rate.
Materials and Methods: The PubMed, Scopus, and Web of Science databases were searched through October 2024 to retrieve relevant papers. Study screening was performed using the RAYYAN software, and meta-analysis was executed with STATA version 18. Publication bias was assessed via Egger's test, and study quality was evaluated using the Joanna Briggs Institute (JBI) critical appraisal tool. Graphical data were digitized using Plot Digitizer.
Results: Initially, 181 articles were identified; after screening and applying inclusion criteria, six studies were included (three for colorectal cancer and three for gastric cancer). A random-effects model was employed, measuring standardized mean difference (SMD) in survival. In colorectal cancer patients, H2RAs were associated with a 5.4895% increase in survival compared to controls (95% CI: 0.49–10.47; P=0.03), predominantly driven by cimetidine. In gastric cancer, survival increased by approximately 2.38% in the treatment group, though not clinically significant.
Conclusion: Current evidence suggests a potential survival benefit of H2RAs, particularly cimetidine, in colorectal cancer, but insufficient for gastric cancer. Larger, well-designed randomized controlled trials (RCTs) are required to confirm efficacy and optimize therapeutic protocols.
- Histamine H2 antagonists
- Gastric cancer
- Colorectal cancer
- Survival rate
How to Cite
References
1. Bray F, Colombet M, Mery L, et al. Cancer Incidence in Five Continents Volume XI: Cancer Today. IARC Scientific Publication. 2021(166).
2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-91.
3. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
4. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. International journal of cancer. 2021;149(4):778-89.
5. Langman MJ, Dunn JA, Whiting JL, et al. Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group. Br J Cancer. Dec 1999;81(8):1356-62.
6. Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug discovery today. 2019;24(10):2076-85.
7. Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev. Aug 15 2012(8):Cd007814.
8. TV T. Healing of a malignant gastric ulcer with cimetidine. JR Coll Surg Edinb. 1988;33:339-40.
9. Armitage J, Sidner R. Antitumour effect of cimetidine? The Lancet. 1979;313(8121):882-3.
10. Harland C, Saihan E. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine. The Lancet. 1989;334(8660):445.
11. Melmon KL, Bourne HR, Weinstein J, Sela M. Receptors for histamine can be detected on the surface of selected leukocytes. Science. 1972;177(4050):707-9.
12. Kumar A. Cimetidine: an immunomodulator. Dicp. 1990;24(3):289-95.
13. Nanda NK, Nath I. Characteristics of histamine receptors present on suppressor T cells in “healthy individuals”. International journal of immunopharmacology. 1985;7(4):587-95.
14. Flodgren P, Sjögren HO. Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. Cancer Immunology, Immunotherapy. 1985;19:28-34.
15. Katoh J, Tsuchiya K, Sato W, Nakajima M, Iida Y. Cimetidine and immunoreactivity. The Lancet. 1996;348(9024):404-5.
16. Kubota T, Fujiwara H, Ueda Y, et al. Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients. British journal of cancer. 2002;86(8):125761.
17. Hansbrough JF, Bender EM, Zapata-Sirvent R, Anderson J. Altered helper and suppressor lymphocyte populations in surgical patients: a measure of postoperative immunosuppression. The American journal of surgery. 1984;148(3):303-7.
18. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer research. 1992;52(20):5765-5769.
19. Espí A, Arenas J, García-Granero E, Martí E, Lledó S. Relationship of curative surgery on natural killer cell activity in colorectal cancer. Diseases of the colon & rectum. 1996;39:429-34.
20. Ali AH, Hale L, Yalamanchili B, et al. The effect of perioperative cimetidine administration on time to colorectal cancer recurrence. American Journal of Therapeutics. 2018;25(4):405-11.
21. Adams WJ, Morris DL. Pilot study—cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1997;80(1):15-21.
22. Lin C-Y, Bai D-J, Yuan H-Y, et al. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial. World Journal of Gastroenterology. 2004;10(1):136.
23. Adams W, Lawson J, Morris D. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut. 1994;35(11):1632-6.
24. Kobayashi K-i, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer research. 2000;60(14):3978-84.
25. Liu FR, Jiang CG, Li YS, Li JB, Li F. Cimetidine inhibits the adhesion of gastric cancer cells expressing high levels of sialyl Lewis x in human vascular endothelial cells by blocking E-selectin expression. Int J Mol Med. Apr 2011;27(4):537-44.
26. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
27. Adams W, Morris D. Short-course cimetidine and survival with colorectal cancer. The Lancet. 1994;344(8939):1768-1769.
28. Svendsen LB, Ross C, Knigge U, et al. Cimetidine as an adjuvant treatment in colorectal cancer: a double-blind, randomized pilot study. Diseases of the colon & rectum. 1995;38:514-8.
29. Finlay I, Dwerryhouse S, King J, King D, Lubowski D, Morris D. The effect of a short preoperative course of cimetidine on the grade of TIL in primary colorectal cancer-a randomised controlled clinical trial. GI cancer. 1999;3(2):121-7.
30. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. British journal of cancer. 2002;86(2):161-7.
31. Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H. Ranitidine as adjuvant treatment in colorectal cancer. Journal of British Surgery. 2002;89(11):1416-1422.
32. Harvey V, Slevin M, Dilloway M, Clark P, Johnston A, Lant A. The influence of cimetidine on the pharmacokinetics of 5‐fluorouracil. British Journal of Clinical Pharmacology. 1984;18(3):421-30.
33. Primrose JN, Miller GV, Preston SR, et al. A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group. Gut. Jan 1998;42(1):17-9.
34. Wotherspoon HA, Anderson JR, Morran CG, Murray GD, McArdle CS. Randomized controlled trial of an H2-receptor antagonist in gastric cancer. British Journal of Surgery. 1997;84(8):1168-9.
35. Tønnesen H, Knigge U, Bülow S, et al. Effect of cimetidine on survival after gastric cancer. Lancet. Oct 29 1988;2(8618):990-2.
36. Hashemi E, Looha MA, Mazaherinia H, et al. Risk of stroke development following retinal vein occlusion: A systematic review and meta-analysis. Survey of Ophthalmology. 2024/11/01/ 2024;69(6):924-36.
- Abstract Viewed: 160 times
- pdf Downloaded: 87 times